Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier ...

1 September 2026 · By · Wire by Fusion42

Published

1 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ir.ocugen.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

Ocugen dosed the first patient in the global Phase 3 trial of OCU410 gene therapy for geographic atrophy secondary to dry age-related macular degeneration, following FDA RMAT designation that enables accelerated development and review. The trial is designed as a single pivotal global study to support a Biologics License Application filing in 2028.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA's RMAT designation for OCU410 fast-tracks approval potential and sets a clear regulatory path, meaning you can plan accelerated development timelines now if you work in gene therapy for vision disorders.

◆ Coverage

1 source · 1 Sep 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyclinical-trialFDA-RMATophthalmologyphase-3biodrug